Cargando…

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect

Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body'...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Julie, Smits, Evelien, Lardon, Filip, Pauwels, Patrick, Deschoolmeester, Vanessa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641952/ https://www.ncbi.nlm.nih.gov/pubmed/26605342 http://dx.doi.org/10.1155/2015/158038

Ejemplares similares

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients
por: Deben, Christophe, et al.
Publicado: (2017)

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
por: Flieswasser, Tal, et al.
Publicado: (2023)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

What next and what to expect?
por: Jacob, Ninan, et al.
Publicado: (2022)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
por: Jiang, Chunyan, et al.
Publicado: (2023)

Detection of HPV and the role of p16(INK4A )overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

Mutism. What to expect?
por: Santos Carrasco, I., et al.
Publicado: (2022)

TAVR in 2017―What we know? What to expect?
por: Kourkoveli, Panagiota, et al.
Publicado: (2018)

Visual SLAM: What Are the Current Trends and What to Expect?
por: Tourani, Ali, et al.
Publicado: (2022)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

What Not to Expect from Koch
Publicado: (1890)

Mucocele of the appendix: what to expect
por: Santos, Sofia Frade, et al.
Publicado: (2022)

The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein
por: Wouters, An, et al.
Publicado: (2014)

What to expect and when to expect it: an fMRI study of expectancy in children with ADHD symptoms
por: van Hulst, Branko M., et al.
Publicado: (2016)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

Prohibition of hormones in animal reproduction: what to expect and what to do?
por: Bó, Gabriel Amilcar, et al.
Publicado: (2023)

What to Expect When You’re Expecting Zika
por: Lazear, Helen M.
Publicado: (2017)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
por: Valind, Anders, et al.
Publicado: (2021)

What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
por: Yin, Jiaxin, et al.
Publicado: (2022)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
por: Omuro, Antonio
Publicado: (2022)

What Do We Expect New Graduate Orthoptists to Do?
por: Horwood, Anna M.
Publicado: (2018)

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
por: Boeckx, Carolien, et al.
Publicado: (2014)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

The COVID-19 surge in Indonesia: what we learned and what to expect
por: Tenda, Eric Daniel, et al.
Publicado: (2021)

Artificial Intelligence in Urooncology: What We Have and What We Expect
por: Froń, Anita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vloh9e24376833lmnld7cs1sgr